Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Study finds Aspyre Lung is a rapid, low-input solution for NSCLC testing

January 2025—Biofidelity announced the publication of data that highlight how Aspyre technology addresses the need for rapid, accessible molecular diagnostics informing actionable genomic variants in cancer (Herlihy SE, et al. Transl Lung Cancer Res. 2024;13[11]:3083–3095). The study demonstrates that Aspyre Lung reagents can be easily set up and run at external laboratories within a few days, producing reliable results even from challenging sample types.

UllCore BSI test gets breakthrough device designation

January 2025—Deepull announced it has received breakthrough device designation from the FDA for its UllCore bloodstream infection test. The test detects 95 percent of pathogens associated with bloodstream infections that may lead to sepsis, as well as select genetic determinants of antimicrobial resistance, and has a turnaround time of one hour. The real-time multiplex PCR system extracts and analyzes total microbial DNA from 8 mL of whole blood.

RightBio Metrics gastric pH indicators

January 2025—RightBio Metrics has announced the availability of its RightSpot Gastric pH Indicators. The FDA-cleared, CLIA-waived product uses pH to confirm gastric acidity for tubes intended to end in the stomach. Other than an x-ray, the primary identifier of a properly placed nasogastric or orogastric tube tip, RightBio says, is a pH reading of 5.5 or less. Each indicator is individually packaged in high-density copolymer foil with proprietary surface treatment to prevent air, light, and humidity from penetrating and can be stored at temperatures between -40°C and 52°C.

QIAstat-Dx instruments, assays get IVDR certification

January 2025—Qiagen announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE marking under the European Union in vitro diagnostic medical devices regulation. The certification includes the QIAstat-Dx analyzer, QIAstat-Dx Rise, and panels for detecting gastrointestinal and respiratory illnesses. The submission for IVDR certification of the QIAstat-Dx meningitis/encephalitis panel is expected in the coming months. The company is transitioning more than 180 products to the IVDR framework.

Microbiologics acquires SensID

January 2025—Microbiologics announced the acquisition of SensID, a manufacturer of reference materials and quality controls for molecular diagnostics, with a focus on oncology and precision medicine. The combination of Microbiologics’ infectious disease diagnostic solutions and SensID’s molecular oncology expertise will ensure they are well positioned to lead in the diagnostic quality control market, according to a Microbiologics press statement.

Trial shows MeMed BV reduces use of unnecessary antibiotics

December 2024—MeMed announced the completion of its first randomized controlled trial to evaluate the MeMed BV test in the United States. Results from this trial demonstrate the clinical utility of the MeMed BV test in promoting appropriate antibiotic use, highlighting its potential to improve patient outcomes and optimize health care decision-making. “This achievement is a critical step toward making MeMed BV the standard for distinguishing bacterial from viral infections and advancing efforts to expand reimbursement coverage,” according to a company press statement.

Qiagen expands QIAcuity dPCR assay portfolio

December 2024—Qiagen announced the launch of 100 assays for its digital PCR platform QIAcuity, for use in the study of cancer, inherited genetic disorders, infectious disease surveillance, and others. The assays are available through the company’s GeneGlobe platform, which integrates predesigned assays with a database of more than 10,000 biological entities, including genes, miRNAs, and pathways.

Bio-Rad expands EQAS program

December 2024—Bio-Rad Laboratories has launched its External Quality Assurance Services specialty immunoassay program. The liquid, independent, and confidential external assessment program consolidates 13 complex and highly tested specialty immunoassay analytes, including procalcitonin, active vitamin B12, interleukin-6, and fructosamine, at normal and abnormal levels.

FDA clears Accelerate Arc system

December 2024—Accelerate Diagnostics announced FDA 510(k) clearance of the Accelerate Arc system and BC kit for use with Bruker’s MALDI Biotyper CA system and MBT-CA Sepsityper software extension. The Accelerate Arc system has a simple workflow that automates positive blood culture sample preparation for direct downstream microbial identification using Bruker’s MBT-CA system.

NeoGenomics launches AML Express

December 2024—NeoGenomics has launched its AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia. The panel includes an extensive list of genes selected for their clinical relevance in AML, covering DNA and RNA alterations, and is intended to be used in conjunction with clinical features and other laboratory results. The turnaround time is three to four days.

MARKETPLACE

TRENDING